ProMIS Neurosciences, Inc. has successfully completed its transition from the Canada Business Corporations Act to the Business Corporations Act in Ontario. This shift, approved by shareholders at the Annual Meeting of Shareholders, is expected to improve internal management functions while maintaining operations in Toronto and British Columbia. Led by Chief Scientific Officer Dr. Neil Cashman, ProMIS also maintains a presence in Cambridge, MA.
ProMIS Neurosciences Inc. is a biotechnology company dedicated to developing antibody therapeutics for neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Multiple system atrophy (MSA). Using innovative thermodynamic and computational techniques, the company's target discovery engine predicts Disease Specific Epitopes on misfolded proteins. ProMIS is listed on both the TSX and NASDAQ stock exchanges.